Nektar Therapeutics (NKTR US): A Good Buying Option in Immuno-Oncology Therapeutic Area
Nektar presented favorable clinical data for its lead candidate, bempeg at a global healthcare conference recently. Bempeg, a potential blockbuster drug, is expected to get approvals starting 2023.
Equity Bottom-Up
226 Views, 13 Dec 2021 00:57
SUMMARY
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network